Company Overview
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Why Investors Should Care
Operating margin of 41.2% supports profitability.
Recent Developments
- Dec 2025 Revenue of $9.68M (+146.7% YoY); net profit $-250.64M.
- 5-Year Trend Long-term compounding — revenue CAGR 1.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.36% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +271.73% |
| 6 Months: | +113.86% |
| 3 Months: | +98.32% |
| 1 Month: | +2.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.84 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PGEN Precigen, Inc. R2KR3KPHARMA | 7.10 | -6.64 | $2.53B | 0.00% | -93.49% | - | 1.36% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 46.02M | - | 39.67M | 45.27M | 32.45M | - | 22.59M | 32.84M | 18.30M | 17.00M | 29.84M | 30.42M | 23.58M | 19.33M | 24.51M | 3.81M | 3.33M | 5.51M | 2.91M | 16.72M | 1.85M | 1.77M | - | - | - | - | 1.34M | - | - | 23.25M | 54.98M |
| Operating Income | -17.43M | -7.92M | -34.40M | -40.53M | -23.22M | -28.82M | -32.59M | -31.38M | -35.27M | -44.75M | -26.49M | -42.24M | -34.81M | -58.33M | -268.12M | -41.85M | -21.51M | -34.70M | -68.72M | -16.60M | -11.83M | -23.01M | -35.17M | - | - | - | - | - | - | - | - | - | - | - | - | -22.60M | - | - | -5.99M | 22.64M |
| Net Income | -40.66M | -38.21M | -32.71M | -64.43M | -49.06M | -28.98M | -44.14M | -31.40M | -18.66M | -39.69M | -27.27M | -46.16M | -65.38M | -57.32M | -340.46M | -60.71M | -38.77M | -53.63M | -169.22M | -56.00M | -43.35M | -29.51M | -41.66M | -17.32M | -20.05M | -29.76M | -19.25M | -17.64M | 87.38M | -22.73M | -20.32M | -19.80M | -23.74M | -58.79M | -23.98M | -54.15M | -26.64M | -146.34M | -7.93M | 20.07M |
| Diluted EPS | -0.37 | -0.34 | -0.28 | -0.55 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.35 | -0.26 | -0.18 | - | -0.09 | -0.10 | -0.15 | -0.10 | -0.09 | 0.44 | -0.10 | -0.08 | -0.08 | -0.10 | -0.23 | -0.09 | -0.18 | -0.09 | -1.06 | -0.02 | 0.05 |
| R&D Expense | 20.38M | 21.60M | - | 25.86M | 28.38M | 29.04M | - | 34.18M | 34.01M | 36.47M | - | 37.27M | 42.05M | 44.88M | - | 33.06M | 34.52M | 31.48M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.48M | - | - | 5.64M | 7.28M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.01M | 13.77M | 23.76M | 71.93M | 173.60M | 190.93M | 219.46M | 151.18M | 90.72M | 31.99M | 14.27M | 26.91M | 6.22M | 3.92M | 9.68M |
| Operating Income | -82.43M | -75.16M | -58.02M | -69.96M | -146.86M | -125.17M | -137.89M | -505.61M | - | - | - | - | -99.76M | -135.03M | -110.51M |
| Net Income | -85.28M | -81.87M | -38.98M | -81.82M | -84.49M | -186.61M | -117.02M | -509.34M | -322.32M | -170.52M | -92.17M | 28.32M | -95.90M | -126.23M | -250.64M |
| Diluted EPS | - | - | - | - | - | - | - | - | -2.09 | -1.02 | -0.47 | 0.14 | -0.39 | -0.47 | -1.37 |
| R&D Expense | 70.23M | 64.03M | 48.14M | 58.98M | 147.48M | 112.14M | 143.21M | 404.59M | - | - | - | - | 48.61M | 53.07M | 41.33M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 151.65M | 469.47M | 576.27M | 982.05M | 949.07M | 846.85M | 716.18M | 455.76M | 314.59M | 359.86M | 215.98M | 151.04M | 145.27M | 155.50M |
| Total Equity | -127.73M | -221.26M | -321.55M | 366.72M | 384.76M | 694.08M | 560.24M | 533.63M | 362.86M | 71.71M | 67.17M | 107.35M | 126.26M | 118.50M | 38.51M | 20.91M |
| Cash & Equivalents | 17.37M | 19.63M | 10.40M | 49.51M | 27.47M | 135.78M | 62.61M | 68.11M | 96.88M | 65.79M | 51.79M | 36.42M | 4.86M | 7.58M | 29.52M | 30.23M |
| Long Term Debt | - | - | - | 1.65M | 8.69M | 7.60M | 7.56M | 7.54M | 211.22M | 186.32M | 171.52M | 179.88M | 0 | - | 0 | 93.17M |
| Total Liabilities | - | - | 66.54M | 88.13M | 166.98M | 277.16M | 379.82M | 300.31M | 337.45M | 384.05M | 247.41M | 252.51M | 89.72M | 32.55M | 78.53M | 134.59M |
| Current Liabilities | - | - | 16.72M | 19.83M | 47.48M | 75.90M | 94.61M | 80.17M | 61.56M | 122.91M | 42.13M | 34.65M | 78.64M | 22.98M | 21.52M | 37.31M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -81.76M | -61.53M | -53.68M | -19.86M | 35.67M | -48.99M | -103.72M | -124.24M | -135.93M | -77.02M | -55.77M | -65.05M | -66.93M | -68.17M | -87.83M |
| Investing Cash Flow | -64.10M | -23.64M | -223.66M | -26.03M | -259.25M | -28.39M | 104.33M | -151.21M | 86.85M | 27.78M | -74.54M | 226.42M | -3.09M | -20.71M | -1.53M |
| Financing Cash Flow | 148.11M | 75.94M | 316.45M | 24.00M | 331.68M | 12.06M | 4.28M | 309.80M | 8.14M | 32.70M | 121.19M | -155.29M | 29.59M | 110.58M | 90.05M |
| Capital Expenditure | -13.00M | -7.49M | -1.53M | -6.37M | -12.75M | -31.63M | -46.67M | -41.59M | -37.88M | -7.53M | -7.25M | -4.92M | -1.54M | -8.58M | -2.00M |
| Free Cash Flow | -94.76M | -69.02M | -55.21M | -26.23M | 22.92M | -80.62M | -150.39M | -165.83M | -173.81M | -84.55M | -63.02M | -69.97M | -68.47M | -76.76M | -89.83M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -1,028.7% | -545.6% | -244.2% | -97.3% | -84.6% | -65.6% | -62.8% | -334.4% | - | - | - | - | -1,602.5% | -3,440.2% | -1,141.1% |
| Net Margin % | -1,064.3% | -594.4% | -164.1% | -113.8% | -48.7% | -97.7% | -53.3% | -336.9% | -355.3% | -533.0% | -646.0% | 105.2% | -1,540.6% | -3,216.2% | -2,588.2% |
| ROE % | 38.5% | 25.5% | -10.6% | -21.3% | -12.2% | -33.3% | -21.9% | -140.4% | -449.5% | -253.8% | -85.9% | 22.4% | -80.9% | -327.8% | -1,198.6% |
| ROCE % | - | -55.7% | -12.9% | -13.2% | -16.2% | -14.6% | -18.0% | -77.2% | - | - | - | - | -77.9% | -109.1% | -93.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Patient Capital Management, LLC | 5.34% | 19.04M | $132.31M |
| 2 | Blackrock Inc. | 4.81% | 17.15M | $119.17M |
| 3 | State Street Corporation | 3.37% | 12.00M | $83.42M |
| 4 | Diametric Capital, Lp | 2.60% | 9.27M | $64.43M |
| 5 | Vanguard Capital Management LLC | 2.22% | 7.91M | $54.95M |
| 6 | Tang Capital Management, LLC | 1.80% | 6.42M | $44.60M |
| 7 | Boxer Capital Management, LLC | 1.44% | 5.15M | $35.79M |
| 8 | Geode Capital Management, LLC | 1.41% | 5.02M | $34.88M |
| 9 | Iridian Asset Management LLC | 1.13% | 4.03M | $28.02M |
| 10 | Occam Crest Management LP | 1.01% | 3.61M | $25.06M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PGEN
Reasons Why Investors Should Consider Betting on PGEN Stock - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNWGZ0LUx2YjlHLWZaZHZJQWU1QWUwUk8ySEh0b0Q5aU4wM05BOTRocWNsZ0tqcUszX2VxMnpBQWpubjNrdHg2OU83VE0tQjVEM2R0NmRPTXppRGNocXJFNzN0TUdRX19uVEZob2loT3UwOVdrZmtOb01aLXJ1Y0VpVUJxUXdzd1lYUnBTZn…
Technical Reactions to PGEN Trends in Macro Strategies - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNZ3ZaWF95ZDJxVFctbU5hZ1RDYldQa0czbE1uYURrYVUtc1lpN3dVaXkzbllvRGI0TE5DM0NnODFINUZNNGRYdEtyaE1CaFNhQVJscjZ5MjI1REREUEdtdjJKcW5Ed3dUckxYUElxVWs4UG5tQTlNRl9TTC04V2R4Z2pveGVPbzBRaElpMj…
Precigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside Estimate - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQc1M5UGlrQ05SWWl0XzJWeTlLTnBGRjlQMm1iMnFITzVYdEFpc1lOQWJ2M0kxRUEyblk3NzRwTzh1LWJQZWZEVWlveWU4Z3A0RzJaT2hpOHdacTY0Q0J6STJZaXl3ak1KUDlsbkgtcXlDd1BTSVVKak9FV1VuSzJrUDlqclhSNHdFdU55en…
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQZ2UydVY3c21wbmhDcllZanFEQl92NjV3OVRtOEtKRlpiUEhfaWVnWXZUMUVORHBvQUFNS3lzNWJCdVpnMlE5ZDdySXhNSlR5RlpQckZRVjkySjAwLWRWZE1mUUx4S0JqRUZXc0MxcXJzN3NkdzRyUW5LOS1mMHU5NEx2eWF1YmMwLXJLM1…
Insider Purchase: Director at $PGEN Buys 3,411 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNMWY3Y3JDVzFQVGNrZ2RUQ2dIRUlibl9aS2ZFRGFsbHdhMm1QTjRNN3dsVlhQeTBydXNGd1dlZjh0Y0dUNi0tLVVKeC1xdHI1RWxkcV9BWk1nYlZ3U3ZrUU9jdElpcElQNG5JeXhTajFiamNkMlpiTUNyTGJfR0ZwNTNUV2hoUENtbERkZE…
Precigen sets 4:30 p.m. ET call for Aug. 4 business update - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQbWpCNDRMY2p0elN5TG1lWDh3N2hSVEZydDVjUlNvaTdTa2xvXzRSMGtCWW9qQnAzVXRSczFhNkxNX2haYmxpeGdjUW5EbWdFVkhEUWoyM3ZqSGM3YWt1RERhbWtaa0l3Si0waVluNEJ6TUtoRUJWVUNpWHVFcTc1ZEduZF9FRVJiVnlMU2…
PGEN — Frequently Asked Questions
What is the current share price of Precigen, Inc. (PGEN)?
As of 2026-09-07 16:24 PDT, Precigen, Inc. (PGEN) trades at $7.10 on NasdaqGS. Its 52-week range is $1.85 to $7.44.
What is the market capitalisation of PGEN?
Precigen, Inc. (PGEN) has a market capitalisation of $2.53B on NasdaqGS.
What is the P/E ratio of PGEN?
PGEN trades at a trailing price-to-earnings (P/E) ratio of -6.64. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 126.84.
Is PGEN a good stock to buy?
This page provides a data-driven analysis of Precigen, Inc. (PGEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.